861 related articles for article (PubMed ID: 11350907)
1. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
Pollack IF; Erff M; Ashkenazi A
Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
[TBL] [Abstract][Full Text] [Related]
2. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
Röhn TA; Wagenknecht B; Roth W; Naumann U; Gulbins E; Krammer PH; Walczak H; Weller M
Oncogene; 2001 Jul; 20(31):4128-37. PubMed ID: 11464279
[TBL] [Abstract][Full Text] [Related]
3. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
Jin H; Yang R; Fong S; Totpal K; Lawrence D; Zheng Z; Ross J; Koeppen H; Schwall R; Ashkenazi A
Cancer Res; 2004 Jul; 64(14):4900-5. PubMed ID: 15256461
[TBL] [Abstract][Full Text] [Related]
4. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
5. NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells.
Hermisson M; Weller M
Cell Death Differ; 2003 Sep; 10(9):1078-89. PubMed ID: 12934082
[TBL] [Abstract][Full Text] [Related]
6. Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells.
Gong B; Almasan A
Cancer Res; 2000 Oct; 60(20):5754-60. PubMed ID: 11059770
[TBL] [Abstract][Full Text] [Related]
7. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.
Nagane M; Pan G; Weddle JJ; Dixit VM; Cavenee WK; Huang HJ
Cancer Res; 2000 Feb; 60(4):847-53. PubMed ID: 10706092
[TBL] [Abstract][Full Text] [Related]
8. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
[TBL] [Abstract][Full Text] [Related]
9. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
Ng CP; Zisman A; Bonavida B
Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
[TBL] [Abstract][Full Text] [Related]
10. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy.
Sayers TJ; Murphy WJ
Cancer Immunol Immunother; 2006 Jan; 55(1):76-84. PubMed ID: 15864587
[TBL] [Abstract][Full Text] [Related]
11. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
[TBL] [Abstract][Full Text] [Related]
12. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
[TBL] [Abstract][Full Text] [Related]
13. APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis.
Roth W; Wagenknecht B; Klumpp A; Naumann U; Hahne M; Tschopp J; Weller M
Cell Death Differ; 2001 Apr; 8(4):403-10. PubMed ID: 11550092
[TBL] [Abstract][Full Text] [Related]
14. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.
Fulda S; Wick W; Weller M; Debatin KM
Nat Med; 2002 Aug; 8(8):808-15. PubMed ID: 12118245
[TBL] [Abstract][Full Text] [Related]
15. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines.
Chawla-Sarkar M; Leaman DW; Borden EC
Clin Cancer Res; 2001 Jun; 7(6):1821-31. PubMed ID: 11410525
[TBL] [Abstract][Full Text] [Related]
16. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
17. Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice.
Xiang H; Nguyen CB; Kelley SK; Dybdal N; Escandón E
Drug Metab Dispos; 2004 Nov; 32(11):1230-8. PubMed ID: 15282212
[TBL] [Abstract][Full Text] [Related]
18. Targeting death receptors in cancer with Apo2L/TRAIL.
Kelley SK; Ashkenazi A
Curr Opin Pharmacol; 2004 Aug; 4(4):333-9. PubMed ID: 15251125
[TBL] [Abstract][Full Text] [Related]
19. Curcumin differentially sensitizes malignant glioma cells to TRAIL/Apo2L-mediated apoptosis through activation of procaspases and release of cytochrome c from mitochondria.
Gao X; Deeb D; Jiang H; Liu YB; Dulchavsky SA; Gautam SC
J Exp Ther Oncol; 2005; 5(1):39-48. PubMed ID: 16416600
[TBL] [Abstract][Full Text] [Related]
20. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
Thai le M; Labrinidis A; Hay S; Liapis V; Bouralexis S; Welldon K; Coventry BJ; Findlay DM; Evdokiou A
Cancer Res; 2006 May; 66(10):5363-70. PubMed ID: 16707463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]